Hauptinhalt
A Pioneer in Rare Diseases
AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. As a specialist in Orphan Diseases, AOP Orphan researches, develops, produces, and distributes innovative solutions in the following therapeutic areas: hematology and oncology, cardiology and pulmonology, neurology and psychiatry, and metabolic diseases. Today AOP Orphan is active at an international level with an export ratio of about 70% and has become a leading company in its home market.
News
AOP Orphan Pharmaceuticals AG today announced the spin off of its 80 % stake in Activartis GmbH, a Vienna-based biotech company with a strong platform for immune-based...
more about "AOP Orphan spins off its stake in Activartis and outlines business strategy"
The Austrian pharmaceutical company AOP Orphan – a European pioneer in the field of rare diseases – has brought on board a health sector expert, Andreas Steiner (53),...
Non-inferiority of anagrelide compared to hydroxyurea in WHO-essential ET. (Prepublished online, Blood, Jan. 11, 2013)
more about "Essential Thrombocythemia (ET) – Convincing data of ANAHYDRET study now published "
